Browse By: Country ι Category ι Tag
Home  »  CBR Pharma Insights

CBR Pharma Insights Market Research Reports

The mission of CBR Pharma Insights is to empower companies within the pharmaceutical industry to make the best business decisions possible through providing them with quality, innovative, strategic market research solutions.

CBR’s market research solutions are focused on being both proactive & reactive in identifying, evaluating, and assessing the key strategic R&D and commercial issues within the pharmaceutical industry.



Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs
GBI Research's latest report, ""Human Drugs For Veterinary Use Current Trends and Future Commercial Prospects for Crossover Drugs"", discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs.
Published Date: May 2016
Published By: CBR Pharma Insights

Price: $2995
Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
 In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Published Date: Jan 2016
Published By: CBR Pharma Insights

Price: $2995
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
The report assesses current market drivers and restraints, mergers and acquisitions (M&A) activity and recent regulatory developments in key national markets. Furthermore, this report analyses leading therapeutic segments in the OTC drugs market, key brands, manufacturers and the potential for new product categories to be created as more prescription-only drugs from diverse therapy areas continue to be considered for OTC approval.
Published Date: Dec 2015
Published By: CBR Pharma Insights

Price: $2995
Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook
Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow.
Published Date: Sep 2015
Published By: CBR Pharma Insights

Price: $2995
Life Cycle Management Strategies - Optimizing revenues and defending generic competition
GBI Research’s latest report, ""Life Cycle Management Strategies Optimizing revenues and defending generic competition"" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on. Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifo
Published Date: Jul 2015
Published By: CBR Pharma Insights

Price: $2995
Biosimilars - Regulatory Framework and Pipeline Analysis
Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal. Biologic products are complex in structure and follow a complex manufacturing process thus, some variation exists between the reference product and its biosimilar. It is very important to assess the variations in biosimilars by comparing with reference product to ensure quality, non-clinical, and clinical properties, which has given rise to the regulatory require
Published Date: Jun 2015
Published By: CBR Pharma Insights

Price: $2995
Mens Health - Changing Male Attitudes to Health to Improve Prognosis and Outcomes
Men’s health refers to conditions that specifically affect males, or those that are not gender-specific but have different outcomes in men. Although still dominated by cardiovascular disease, men’s health is increasingly focusing on other conditions and the wellness of the man overall. There are many different factors that impact on men’s health, making it a unique therapy area; these include biological, social, psychological and economic factors. In addition, men are exposed to a number of risk factors that make specific diseases and conditions more prevalent in the male population, such a behavioural risk and work-related risk factors. Lifestyle factors are also known to be at the root cause of many diseases and conditions that affect men, and while some changes can
Published Date: Mar 2015
Published By: CBR Pharma Insights

Price: $2995
Womens Health - Assessing the Need for a Targeted and Specialized Approach
Many of the diseases and conditions that affect mainly women are interlinked with similar root causes; however, placing all of the pieces of the puzzle together to ensure a cohesive management strategy remains a challenge. Women’s Health is a collection of multi-factorial conditions and diseases that solely affect or are more prevalent in females. Many can have a serious impact on women’s overall long-term health and quality of life. There are a number of causes of Women’s Health diseases, ranging from hormonal fluctuations associated with specific points in a woman’s life through to psychological issues underpinning certain lifestyle disorders. As these causes and the courses and consequences of these diseases become better understood, the importance of target
Published Date: Jan 2015
Published By: CBR Pharma Insights

Price: $2995
Opioids Market Overview to 2023 - Opioids in Emerging Markets
The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness. There is a high level of unmet need for pain control in both cancer and HIV/AIDS, and serious concerns have been raised regarding inadequate pain management in the emerging markets. However, this is
Published Date: Nov 2014
Published By: CBR Pharma Insights

Price: $2995
Opioids Market Overview to 2023 - Opioids in Western Europe
The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%). Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadeq
Published Date: Oct 2014
Published By: CBR Pharma Insights

Price: $2995
Pediatric Drug Development - Regulatory challenges and commercial opportunities
Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).  Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly. In the US more than 350 product labels include new pediatric information and more than 130 products have undergone a pediatric
Published Date: Jul 2014
Published By: CBR Pharma Insights

Price: $2995
Adaptive Licensing - A Holistic Approach to Drug Development and Regulation
Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs). After the initial license is granted, the entry to market is heavily restricted, and the patient population is carefully monitored through observational studies, electronic devices and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full license permission. By improving the alignment of stakeholder need
Published Date: Jul 2014
Published By: CBR Pharma Insights

Price: $2996
Biosimilars - Biosimilars on the cusp of a new era
The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies – the FDA and EMA.  Moreover, there are some concerns around biosimilar use, for example with physicians worried about how similar certain drugs are and whether they can safely be used in particular patient populations such as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected that the biosimilar market will continue to
Published Date: Jul 2014
Published By: CBR Pharma Insights

Price: $2995
Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases
More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are id
Published Date: Feb 2014
Published By: CBR Pharma Insights

Price: $3900
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges
Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is increasingly becoming a focus. Research into therapeutic vaccination for patients already affected by a disease is also gathering pace. There are several different approaches to preventative vaccination, most of which have been effectively employed to reduce the incidence of certain diseases or, in some cases, eradicate them completely. Scope This report providers readers with an understandin
Published Date: Feb 2014
Published By: CBR Pharma Insights

Price: $3900
Telemedicine - The Future is Now for Moving Telemedicine into Mainstream Treatment
Telemedicine is a creation of the 20th century. First used primarily for military and space applications, it has been becoming more widespread in use in recent years. There are three main types of telemedicine applications: store-and-forward, remote monitoring and interactive services.Interest in telemedicine is growing globally, particularly in the fields of teleradiology, telepathology and teledermatology. Globally, cost is seen as the major barrier to telemedicine programs. In the US, telemedicine has been promoted as a way to serve rural populations, but in the next few years it is expected to spread to a much wider patient base.A number of key challenges still need to be addressed for the use of telemedicine to become more widespread in the US. Licensing and reimbursement remain major
Published Date: Jul 2013
Published By: CBR Pharma Insights

Price: $3900
Immunotherapy Development Strategies - An Evolving Market with Significant Potential but with Challenging Hurdles to Overcome
Although immunotherapy was first recognized over 100 years ago, it has only become an important therapeutic tool in recent decades. The immune system can be harnessed in one of several ways to tackle various diseases such as cancer, infection, auto-immune disease and inflammatory diseases.The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing.Market access presents a significant hurdle for immunotherapeutics, as many are high cost and do not deliver the measurements required for traditional cost-effectiveness assessments.Oncology has been a primary area of focus for immunotherapeutics, largely due to the po
Published Date: Jul 2013
Published By: CBR Pharma Insights

Price: $3900
The Politics of Pharma - Washington, States and the Courts Impact on the Industry
Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways.The Medical Device Excise Tax, a component of the 2010 health care reform legislation, survived a pre-election Congressional effort at repeal, but a coalition of House Republicans and Democrats from key states are looking to try again. Post-election, another bi-partisan congressional group is pushing for the FDA to impose stricter regulations on certai
Published Date: Apr 2013
Published By: CBR Pharma Insights

Price: $3900
R&D Productivity - The State of Research and Development in the BioPharmaceutical Industry
As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model?Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured. Public companies may release overall expenses, yet allocations to specific products or franchises may be more di
Published Date: Apr 2013
Published By: CBR Pharma Insights

Price: $3900
Companion Diagnostics - Streamlining drug development and advancing personalized medicine
used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize riskCompanion diagnostics can allow for a specific patient population to be identified which will ensure those patients who are most likely to respond are recruited for clinical trials and receive the therapy once the product is launched. Companion diagnostics can help to rationalize treatment decisions, with specifics such as accurate dosing, risks of adverse events and diagnostics being made possible through these tests. Through the use of companion diagnostics, the right treatment can be delivered to the right patient at the right time, delivering greater value and optimizing healthcare resource utilizationOncology has been the most active arena
Published Date: Apr 2013
Published By: CBR Pharma Insights

Price: $3900
Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy
The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a re
Published Date: Mar 2013
Published By: CBR Pharma Insights

Price: $3900
Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed
The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies. While overall survival is the gold standard endpoint, achieving this is challen
Published Date: Jan 2013
Published By: CBR Pharma Insights

Price: $3900
Electronic Health Records - Charting the Future of Health Care
Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were further bolstered by programs in the 2010 health care reform legislation which promoted Accountable Care Organizations.After the results of the November elections and the Supreme Courts ruling upholding the individual mandate, the future for health care reform would look more sure. However, recently some Republican members of congress have turned their
Published Date: Jan 2013
Published By: CBR Pharma Insights

Price: $3900
The Digital Patient - A Snapshot of the Digital Landscape of Patients and Caregivers
The advent of mobile phones and other devices has opened up new channels for pharmaceutical marketers to reach patients and caregivers. The Pharma industry as a whole is late to the digital game so logically patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional moment.This is a tremendous opportunity but not one without challenges one of the biggest obstacles being lack of clear direction from the FDA around appropriate use of social media. Based upon this statement by Ernest Voyard, the FDAs senior regulator council, guidance around appropriate use of social media will not be issued in the near future. We are w
Published Date: Nov 2012
Published By: CBR Pharma Insights

Price: $3900
Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome
Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.The report, Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome has
Published Date: Sep 2012
Published By: CBR Pharma Insights

Price: $3900
Emerging Pharmaceutical Technologies - Stem cells
Emerging Pharmaceutical Technologies - Stem cells Summary Stem cell technology is set to play a significant role in the pharmaceutical industry of the future. The opportunities for using stem cells across drug discovery, disease research, drug development and treatments are wide-ranging, yet largely unproven at present. Even if companies are not interested in joining the first wave of stem cell therapy developers, they need to be monitoring this sector in order to understand future competitive threats. The impact on drug discovery & development will impact the whole industry through a range of changes, from greater understanding of diseases to improved screening of drug candidates. With R&D pipelines across the industry still under pressure, collaboration between academia, stem cell s
Published Date: Aug 2012
Published By: CBR Pharma Insights

Price: $3900
Accountable Care Organizations - A Building Block for the Future of Health Care
The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets.The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration. This may mean some changes for pharmaceutical companies looking to work with ACOs. Promotional materials will need to highlight evidence-based medicine findings an
Published Date: Aug 2012
Published By: CBR Pharma Insights

Price: $3900
Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End
A good clinical development plan will ensure success throughout the product lifecycle.In todays cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout.The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale of product development.A variety of approaches should be adopted to ensure a robust clinical development plan is developed. Early initiation of the clinical development plan is critical for the execution of a successful product development process.A proactive approach to the processes and objectives encompassed in the clinical development plan must be adopted..The re
Published Date: Jun 2012
Published By: CBR Pharma Insights

Price: $3900
Diversification in the Pharmaceutical Industry - Essential For Survival or an Unnecessary Distraction?
Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown. The industry remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties.On one hand some companies believe that diversification is necessary to survive and thrive in the current difficult operating environment and that it offers specific advantages going forward.On the other hand some companies believe that a narrow focus is necessary to optimize the prescription pharma business model and that diversification represents giving up.Ultimately, it is the nature of the
Published Date: May 2012
Published By: CBR Pharma Insights

Price: $3900
The Next Generation of Pharmaceutical Marketing Strategies - Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders
Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters.Multiple factors are driving the need for industry-wide change. One of the biggest contributors is the escalating cost of healthcare. In an effort to stop and reverse this trend a great emphasis is being placed on improving the delivery of care and outcomes for patients. In addition, the number of stakeholders involved in treatment decisions has expanded beyond the physician to include payers and patients. These are just two examples o
Published Date: Mar 2012
Published By: CBR Pharma Insights

Price: $3900
Pharmaceutical Pricing Strategies - Changing approaches to meet challenging times
The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs. Consequently, prices have come under scrutiny, with many older products having discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price.Novel pricing policies, such as value based pricing and external price referencing, are being employed by governments to regulate pharmaceutical prices and are expected to have a significant impact on prices and profitability in the future.The report, Pharmaceutical Pricing Strategies - Changing approaches to meet challenging times, uses case study analysis to support companies with their strategic pricing strategies w
Published Date: Mar 2012
Published By: CBR Pharma Insights

Price: $3900
The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace
Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place.The health care reform legislation in 2010 was the product of extended debate and compromise. The legislation will mean huge changes for the insurance industry if it is enacted. However, the more controversial aspects of the legislation, particularly the Mandate for health insurance, have resulted in numerous challenges.For pharmaceutical companies, there are potential gains and challenges. Much of the 2010 health
Published Date: Mar 2012
Published By: CBR Pharma Insights

Price: $3900
Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management
Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. Its potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy.Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product. This has become necessary as increasingly cost conscious healthcare providers promote the use of generic thera
Published Date: Jan 2012
Published By: CBR Pharma Insights

Price: $3900
Looking at Senior Long-term Care - Where will the market go?
In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing. Memory Care facilities, for those with Alzheimers Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus.Long-term care is becoming increasingly important as a market with the US population aging. Over 65s are now the fastest growing population group in the US. With the Baby Boomer generation only just beginning to turn 65 in 2011, the next 20 years will see tremendous growth in the long-term care population.Marketing to long-term care patients can have unique challenges due to the staffing of institutions an
Published Date: Dec 2011
Published By: CBR Pharma Insights

Price: $3900
Risk Evaluation and Mitigation Strategies - Adaptation in an evolving system
s. As an evolution of this process, the agency established the Risk Evaluation and Mitigation Strategies (REMS) program in 2008.Products can be approved with a Medication Guide only REMS, a Communication Plan REMS which incorporates a Medication Guide together with educational materials for providers or it can require Elements to Assure Safe Usage (ETASU).There has been substantial criticism of the current REMS system from pharmaceutical companies, as well as from providers and dispensers. The FDA is moving to address some of these criticisms by trying to establish greater standardization across the system.The report, Risk Evaluation and Mitigation Strategies - Adaptation in an evolving system, has been written to provide insights, analysis, and support to the pharmaceutical teams working
Published Date: Oct 2011
Published By: CBR Pharma Insights

Price: $3900
The Impact of Generics on Pharmaceutical Growth Opportunities - A growing threat that offers future opportunities
While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate the trend.Combined with this, pharma is experiencing a wave of blockbuster patent expiries, with almost $30 billion in US sales (at 2010 levels) exposed by the largest 10 drugs which are expected to experience generic competition for the first time in 2011-2012.As a result, companies must focus on optimizing their late-stage lifecycle management strategies to maximize at-risk product revenues. But at the same, time generics should be considered not just as a threat but also as an opportunity going forward.The report, The Impact of Generics on Pharmaceutical Growth Opportunities - A gro
Published Date: Oct 2011
Published By: CBR Pharma Insights

Price: $3900
Accelerating Drugs to Market - In Search of Opportunity Along the Drug Development & Approval Pathway
The commercial life of a drug and the sales trajectory achieved are dependent on a multitude of factors. One critical factor in achieving success is the ability to bring a product to market quickly to gain competitive advantages and to start recouping development costs. From product concept to market, there are a number of potential areas of opportunity for accelerating a drug through to FDA approval. Many initiatives tie to scientific and technological innovations in the research and development realm while others are tied to the regulatory pathway.The four main FDA mechanisms that can play a role in speeding drugs to market are Accelerated Approval, Priority Review, Fast Track and orphan designation. All of these were designed with the intention of facilitating development of drugs that
Published Date: Sep 2011
Published By: CBR Pharma Insights

Price: $3900
Pharmaceutical Sales Force Effectiveness - Rethinking the Current Sales Model
The pharmaceutical industry is facing change on a monumental scale. Patents on key products are expiring, the flow of new products from pipelines is low, and the number of decision makers involved has increased. Add to this mix Health Care Reform and the way a company develops, markets, and sells their products is impacted on some level. The next 5 10 years will be an exciting time to be a part of this industry as it undergoes a transformation.In this new environment sales representatives have less time with physicians, payers influence prescribing decisions, and generics are dispensed the vast majority of the time. On the commercial side of the business, companies are exploring alternatives to the Reach and Frequency sales model that served them well for many years.Pharmaceutical Sales F
Published Date: Aug 2011
Published By: CBR Pharma Insights

Price: $3900
Pharmaceutical Cliff Diving - Assessing the key challenges that will re-shape the industry
In a challenging period for the pharmaceutical industry, first quarter results show an interesting picture. The generics industry, unsurprisingly, showed strong growth; lacking the impact of the patent cliff, the biotech industry also grew. For big pharma, sales were flat to negative for most, but a number of companies found that their work to streamline and restructure were showing positive results, with Q1 profits up.The industry faces challenges from the government sector as well: increasing surveillance from the FDA, and the possibility of heightened penalties for pharma executives. Uncertainty over the direction of last years Health Care Reform legislation also continues. From the Supreme Court, the industry has primarily found challenges overcome, with the Court upholding pay-for-del
Published Date: Jul 2011
Published By: CBR Pharma Insights

Price: $3900
The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market
Biosimilars are attracting significant attention at present as companies from all sectors of the biopharmaceutical market are investigating the opportunities they present.Opinion is split as to the true potential of this market with some predicting it will grow to the multi-billion dollar level within five years, while others point to the limited impact of biosimilars in Europe to date to suggest that it will never be a major threat to branded biologics.Biosimilar pipelines are rapidly shifting away from the initial focus on the older, less complex, biologics towards the higher earning monoclonal antibodies as well as developing, so called, biobetters similar biologics which offer improvements over the originator.The Coming Age of Biosimilars - Regulatory developments and alliance strateg
Published Date: May 2011
Published By: CBR Pharma Insights

Price: $3900
New Product Launch Strategies - Initiating Market Entry with Sound Strategies and Tactics
Product launch strategies and tactics are the keys to a successful market entry and can impact product performance for years down the road.The launch of a product on a strong trajectory can mean exponential growth; however lost opportunities at the entry of a product to a market can necessitate re- launch and re-branding activities which can be costly and cumbersome. Additionally, these Plan B tactics are not always effective. Successful product launch strategies start with the assessment of market size and potential as well as an understanding of the key market challenges.This consultancy style report provides a summary of the important strategic and tactical factors to consider when launching a new pharmaceutical product. Beginning with an historical review of the changing landscape for
Published Date: Apr 2011
Published By: CBR Pharma Insights

Price: $3900
The Impact of Economic Factors on the Pharmaceutical Industry - Where the Next Five Years Will Take Us
Although there is debate about the direction the US economy is headed, most analysts agree that though we are moving in towards a recovery, labor markets will be slow to rebound.The economic downturn that were currently in has brought a number of challenges for the pharmaceutical industry, such as loss of health coverage through unemployment, decreasing health benefits for those still employed, and a lessened ability to pay for co-pays or prescriptions.As a result, we are seeing increased issues of medication adherence by todays patients. Moving forward, price pressures, from public payers, insurance companies and individuals, will lead many to replace branded products with generics. Due to these and other factors, the generics sector of the pharmaceutical industry is set to grow at a fast
Published Date: Mar 2011
Published By: CBR Pharma Insights

Price: $3900
Pharmaceutical & Biotech Licensing Strategies - Driving Revenue through Partnerships
In todays pharmaceutical industry, multiple factors looming patent expirations, depleted pipelines, increases in R&D expenditures, payer pressures, and tighter FDA regulations- have forced Big Pharma to change its business model. The evolving model is one grounded in collaboration. Companies are no longer relying solely on their own internal R&D programs for innovation; they are looking outside of their four walls. Some have labeled this search and development.There are many types of alliances that support this collaborative model. One type, in-licensing products, is very appealing. The number of licensing agreements has grown year over year since 2007. The top companies are interested in several key therapeutic areas including oncology, CNS, and infectious disease. These companies are al
Published Date: Jan 2011
Published By: CBR Pharma Insights

Price: $3900
Managed Care and the Pharmaceutical Industry - Top Issues, Health Care Reform and the Inter-linkages Bringing them Together
The managed care and the pharmaceutical industries have many conflicting goals. Managed care organizations are looking to reduce or at the least maintain drug costs, while pharmaceutical companies seek to increase the sale of their brand-name drugs. Common ground between the two industries can be difficult to find.Shared goals do exist, though. Both the managed care industry and the pharmaceutical industry have a stake in how prescription drugs impact the cost and quality of health care. Both industries would like to see treatment persistence increase and, to this end, are continually investing in the research and development of disease management and medication compliance programs. Finally, both the managed care and the pharmaceutical drug industry are heavily influenced by the each oth
Published Date: Dec 2010
Published By: CBR Pharma Insights

Price: $3900
Personalized Medicine - Opening Doors and Overcoming Challenges
Over the last 20 years personalized medicine has grown as tool in patient treatment. Personalized medicine uses a patients genetic information to help tailor treatment to avoid side effects, identify what treatments will and wont work and establish a pre-disposition towards certain diseases.Personalized medicine has been focused to a great degree in the oncology area, where on average an individual patient may find more than 70% of medicines ineffective for them. In the last few years this has begun to change as more personalized medicines have been developed outside of the oncology field. The spread of personalized medicine to other fields has increased the challenge of physician uptake, with many GPs not feeling comfortable ordering genetic tests.Personalized medicine faces a number of r
Published Date: Nov 2010
Published By: CBR Pharma Insights

Price: $3900
The Perception of the Pharmaceutical Industry - What the Web is Saying About Health Care Reform, Drug Safety, And Prescription Costs
Three of the most important areas that make up the publics perception of the pharmaceutical industry center around its involvement in the recent health care reform, the safety of its medication, and the cost associated with filling a prescription.Even though the industry will be contributing approximately $80 billion in fees and rebates towards the recent US health care reform legislation, the consumers perception is that they have actually contributed negatively to it.Consumers feel that the high prices they are paying for their medication, which some believe is not truly safe, are not fully justified in this poor economic climate where the unemployment rate is high and health care costs are escalating. Pharmaceutical companies, and the industry as a whole, have a lot of work to do to in
Published Date: Oct 2010
Published By: CBR Pharma Insights

Price: $3900
The Aging Population - How and Where to Succeed with the Over 50 Crowd
America is aging. People are leading longer, healthier lives; a contributing factor to an increase in the proportion of the population over the age of 65. In 2010, older Americans make up 13% of the total population. By 2050, this figure is estimated to grow to 20% increasing the burden placed on society.Todays Seniors are happy, active, and living in the communities of their choice. This independence, which is highly valued, is sustained in part through the efforts of informal caregivers and home and community-based services. While they feel good, the majority of Seniors are living with at least one chronic condition.Spending on health care in the U.S. is on the rise and it is largely understood that the population with multiple chronic illnesses drives the majority of these costs. What
Published Date: Sep 2010
Published By: CBR Pharma Insights

Price: $3900
Social Media and e-Communication within the Pharmaceutical Industry - Understanding the future of direct-to-consumer marketing
The use of social media is allowing people to organize and discuss any topic or cause of interest to them with other people around the world via the internet. Through social networking sites like Twitter and Facebook, disease-specific communities, blogs, and other social internet applications, the opportunities for sharing information have increased at a significant pace. Today, three-fourths of American adults use the internet regularly and four-fifths of American adult internet users participate in social media.This involvement in social media has created an environment of strong consumers and consumer advocates who wield considerable influence over the image of products and corporations. 83% of internet users search for health or medical information via the internet, enhancing the overa
Published Date: Aug 2010
Published By: CBR Pharma Insights

Price: $3900
The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding and Adaptation
After a hotly contested national debate, healthcare reform legislation was passed in the spring of 2010. The legislation contains many long-term benefits for the pharmaceutical industry, but the industry must continue to play an active role in legislation implementation to ensure those benefits are realized.Through the new laws, there are both wins and losses for the pharmaceutical industry, such as changes effecting Medicare/Medicaid, health insurance coverage expansion & protection, taxation and patent protection. However, on balance most changes hold significant long-term potential for the industry.While pharma played a very important role in promoting health reform during the debate over change, the work is not done. Many of the greatest potential benefits of the legislation including
Published Date: Jun 2010
Published By: CBR Pharma Insights

Price: $3900
Emerging Market Strategies - Mapping the opportunities for pharmaceutical expansion
With a variety of factors impacting pharmaceutical growth in the traditional markets (the US, 5EU and Japan) price controls, moves towards generics, healthcare reform, market saturation the emerging markets (EMs) hold increasing potential to drive future product sales and overall company revenues.The different situations which exist within each emerging market offer a wide variety of opportunities along with their own set of accompanying challenges. In order to best break in and position themselves within the various emerging markets, pharmaceutical companies are employing several different strategies. These strategies include: sales force growth, tiered pricing, generics, acquisitions/partnerships and an urban vs. rural focus.The Emerging Markets Strategies report assesses why companies
Published Date: Apr 2010
Published By: CBR Pharma Insights

Price: $3900
Optimizing Pipeline Performance - Maximizing Future Sales Opportunities through Pipeline Optimization & Benchmarking Strategies
In todays pharmaceutical industry, optimizing pipeline performance is more important than ever before. With major patent expirations looming, an increase in competition coming from generics, healthcare reform taking shape, and a greater amount of scrutiny being seen with new drug approvals, having an efficient R&D process is crucial to a companys future success.This report assesses the key issues impacting pharmaceutical product development, while providing insight & analysis into the key strategies being used today to optimize pipeline performance. CBR Pharma Insights also examines how the top companies have laid out their research & development efforts and which therapeutic areas are seeing the most activity overall.Scope- Key issues affecting pharmaceutical company pipelines in 2010- Op
Published Date: Mar 2010
Published By: CBR Pharma Insights

Price: $3900
The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned
2009 has been a turbulent year for the global economy and the increasing interconnectivity of business has amplified its impact on the pharmaceutical industry. As a result of the global recession, the pharmaceutical industry has seen a greater urgency to adapt its ways in order to continue to sustain any substantial growth.Several key events & trends have been seen over the past year which will change the way the pharmaceutical industry looks going forward. Some of these include: the return of the mega-merger, healthcare reform in the United States, the Swine Flu pandemic, and impact of patent expires & generics.CBR Pharma Insights report, The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned will help support your business planning initiatives as it identifies, revi
Published Date: Dec 2009
Published By: CBR Pharma Insights

Price: $3900
Managed Care Trends and Strategies - The Voice of Managed Care on the State of Relations Between Managed Markets & the Pharmaceutical Industry and Opportunities for Partnership
Managed care has evolved over the past century to become a central part of the process of delivering health care to patients. Starting with the formation in 1917 of the first prepaid medical plan by physicians in cooperation with corporations and unions, and continuing with the establishment of Health Maintenance Organizations with governmental assistance in the 1970s, health care as we know it today has evolved through a series of events and legislations. Most recently, the initiation of Medicare Part D through the Medicare Modernization Act in 2003 has further sealed the relationship between managed markets and the pharmaceutical industry.Today, managed care organizations are even more important as customers for pharmaceutical companies due to increased restrictions being placed on direc
Published Date: Dec 2009
Published By: CBR Pharma Insights

Price: $3900
The Economy and the Pharmaceutical Industry - Adherence to Drug Treatments and How the Current Economic Environment is Affecting Patients Treatment Choices
The ongoing US recession is affecting consumers behavior in the healthcare market. The rising unemployment rate means that fewer individuals are covered under generous employer sponsored health insurance plans. Many people who lose their jobs also lose their ability to cover the costs of healthcare, including prescription drugs. Being un-or under-insured drives consumers to seek out ways to save money on medical costs, or in some cases to skip medical care entirely.Some individuals qualify for state-subsidized programs such as Medicaid; however membership in these programs also impacts consumers healthcare decisions by encouraging the use of cheaper generic drugs rather than brand name options.The goal of the Adherence to Drug Treatments in Todays Economy report is to provide an executive-
Published Date: Nov 2009
Published By: CBR Pharma Insights

Price: $3900
Pharmaceutical Mergers and Acquisitions - M&A in the Biopharmaceutical Industry and the Impact on Innovation
The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).Mergers and Acquisitions have defined the landscape of the pharmaceutical and biotechnology industries, both historically and today. The strategic targeting behind corporate acquisitions, as well as mergers, are focused on intellectual property, sales force efficiency, streamlining research & development, and reorganizing other key business areas.This report provides a
Published Date: Sep 2009
Published By: CBR Pharma Insights

Price: $3900
Lifecycle Management Strategies - Key tools to maximize return on investment in a tough healthcare environment
Pharmaceutical companies continuing to face the challenges of declining R&D productivity and rising costs, while trying to negotiate an increasingly risk averse and cost constrained healthcare marketplace, need to focus on improving their lifecycle management strategies in order to maximize their portfolios sales over the long term.In an increasingly difficult operating environment, optimizing LCM strategies is an important way for companies to maximize their return on investment.However, the changing environment is also impacting the effectiveness of the LCM strategies themselves. This means that LCM selection and implementation needs to be a dynamic and adaptive process and up to date market intelligence is key. Effective LCM planning begins early in the lifecycle of a drug, ideally duri
Published Date: Sep 2009
Published By: CBR Pharma Insights

Price: $3900
Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena
The nature of biotechnology has, up until recently, prevented the threat of generic intrusion on product sales. Biologics are difficult to replicate compared to small molecules and even slight differences in manufacturing processes could lead to significant clinical differences.The US government is poised to address the need for a process by which similar biologics or proteins can be approved and brought to market. Two legislations are on the table, one more closely resembling recently enacted laws in Europe.This report uncovers how the US biotechnology and biopharmaceutical industry will soon change in dramatic ways as we see the introduction of biosimilars. While the actual laws and legislation that will usher in this new era have yet to be finalized, players are already setting up to be
Published Date: Jun 2009
Published By: CBR Pharma Insights

Price: $3900
The Obama Administration and the Pharmaceutical Industry - Overview of the 2009 Recovery Act and the 2010 Federal Budget
President Obama has made healthcare reform one of his administrations top priorities. Towards this goal, several billion dollars have been provided through the Recovery Act and 2010 Budget for initiatives that are intended to make the US healthcare system safer and more cost-effective. These include - - conducting comparative effectiveness research trials to help physicians and patients make more informed decisions at the point-of-care;- adopting health information technologies, such as ePrescribing, telemedicine and electronic medical records (EMR);- expanding Medicaid and strengthening Medicare by focusing on program integrity issues;- promoting more affordable drug options by expediting the approval of generic drugs and opening the market to consumers who would like to buy drugs from ne
Published Date: Jun 2009
Published By: CBR Pharma Insights

Price: $3900
The New Pharmaceutical Sales Force - Key Trends Shaping Future Sales Strategies
There are few companies in the pharmaceutical industry that are not experiencing decreased revenue and profitability. At the same time, the costs associated with developing a new drug and bringing it to market continues to grow. In order to increase value for shareholders, pharmaceutical companies will need to restructure their businesses from top to bottom. Many jobs will be lost, moved to other markets or redefined to fit the evolving pharmaceutical business model.In part I of a two-part series on sales and marketing to the pharmaceutical industry, this consultancy-style report provides an overview of the evolution of pharmaceutical sales strategy. The focus of our analysis is on how ongoing layoffs and revised regulations are contributing to the restructuring of the pharmaceutical sales
Published Date: Apr 2009
Published By: CBR Pharma Insights

Price: $3900
Key Trends Shaping Future Marketing Strategies - Maximizing Your Online Channels
Due to decreasing sales growth, the pharmaceutical industry as a whole has seen a steady decline in consumer marketing budgets. At the same time, it has experienced an increase in both competition from generics and oversight by the FDA.Mass media advertising has long been the cornerstone of brand-building in the US pharmaceutical market. However, in the current commercial and regulatory environment, brand managers are going to need to look for more targeted and creative solutions to both reach and retain potential patients.In part 2 of a two-part series on sales and marketing to the pharmaceutical industry, this consultancy-style report provides an overview of the challenges facing pharmaceutical companies as they market their products in 2009 and beyond. Opportunities for growth and innov
Published Date: Apr 2009
Published By: CBR Pharma Insights

Price: $3900
The Pharmaceutical Industry 2009 - The Key R&D Trends Impacting New Product Development
Despite the current economic downturn, pharmaceutical research and development spending continues to play a vital role in the pharmaceutical industry.Recent trends indicate a consolidation of efforts through numerous acquisitions, both intra-pharmaceutical as well as purchases of biotechs by big pharma. In addition, pharmaceutical companies are narrowing the focus of their research and development units through a more strategic concentration on key chronic illnesses. Current challenges to FDA approvals have influenced this reduction in the number of products under development.In part I of our two-part series on the outlook for the pharmaceutical industry, we assess the trends taking place around new product research and development. This consultancy-style report provides an overview of the
Published Date: Apr 2009
Published By: CBR Pharma Insights

Price: $3900

Back To Top